Literature DB >> 636125

Dimethyl sulfoxide in treatment of inflammatory genitourinary disorders.

S W Shirley, B H Stewart, S Mirelman.   

Abstract

Intravesical dimethyl sulfoxide (DMSO) has been used in the treatment of 213 patients with various inflammatory conditions involving the lower genitourinary tract, including intractable interstitial cystitis, radiation cystitis, chronic prostatitis, and chronic female trigonitis. Significant symptomatic relief has been achieved in the majority of patients so treated, and no systemic or local toxicity has been noted. Some patients failed to respond entirely, and others relapsed after DMSO treatment periods of several months, ultimately coming to augmentation cystoplasty or urinary diversion. However, because of its simplicity and ease of administration, intravesical DMSO therapy is recommended in all noninfectious or non-neoplastic inflammatory conditions presenting initially with severe symptoms, or that have failed to respond to conventional therapy.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 636125     DOI: 10.1016/0090-4295(78)90118-8

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  19 in total

Review 1.  Advances in intravesical therapy for urinary tract disorders.

Authors:  Pradeep Tyagi; Mahendra Kashyap; Harvey Hensley; Naoki Yoshimura
Journal:  Expert Opin Drug Deliv       Date:  2015-10-19       Impact factor: 6.648

Review 2.  Recent advances in intravesical drug/gene delivery.

Authors:  Pradeep Tyagi; Pao-Chu Wu; Michael Chancellor; Naoki Yoshimura; Leaf Huang
Journal:  Mol Pharm       Date:  2006 Jul-Aug       Impact factor: 4.939

3.  Long-term outcomes of intravesical dimethyl sulfoxide/heparin/hydrocortisone therapy for interstitial cystitis/bladder pain syndrome.

Authors:  Yik N Lim; Peter Dwyer; Christine Murray; Debjyoti Karmakar; Anna Rosamilia; Elizabeth Thomas
Journal:  Int Urogynecol J       Date:  2016-12-16       Impact factor: 2.894

4.  Potential Use of Dimethyl Sulfoxide in Treatment of Infections Caused by Pseudomonas aeruginosa.

Authors:  Qiao Guo; Qiaolian Wu; Dangdang Bai; Yang Liu; Lin Chen; Sheng Jin; Yuting Wu; Kangmin Duan
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

5.  Dimethyl sulfoxide induces heme oxygenase-1 expression via JNKs and Nrf2 pathways in human umbilical vein endothelial cells.

Authors:  Chao Liang; Zhanggang Xue; Jing Cang; Hao Wang; Ping Li
Journal:  Mol Cell Biochem       Date:  2011-04-30       Impact factor: 3.396

6.  Dimethyl sulfoxide inhibits phagocyte influx into infected pleural spaces and phagocyte locomotion in vitro.

Authors:  V B Antony; S A Sahn; J E Repine
Journal:  Inflammation       Date:  1983-12       Impact factor: 4.092

Review 7.  Etiology: where does prostatitis stop and interstitial cystitis begin?

Authors:  Evan R Eisenberg; Robert M Moldwin
Journal:  World J Urol       Date:  2003-05-28       Impact factor: 4.226

8.  Botulinum a toxin/dimethyl sulfoxide bladder instillations for women with refractory idiopathic detrusor overactivity: a phase 1/2 study.

Authors:  Steven P Petrou; Alexander S Parker; Julia E Crook; Alexandra Rogers; Dorothea Metz-Kudashick; David D Thiel
Journal:  Mayo Clin Proc       Date:  2009-08       Impact factor: 7.616

Review 9.  Current recommendations for bladder instillation therapy in the treatment of interstitial cystitis/bladder pain syndrome.

Authors:  Marc A Colaco; Robert J Evans
Journal:  Curr Urol Rep       Date:  2013-10       Impact factor: 3.092

10.  Chronic prostatitis: Current concepts.

Authors:  Ram Vaidyanathan; Vibhash C Mishra
Journal:  Indian J Urol       Date:  2008-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.